STORAGE
Store in a cool place. Protect from light.
PRESENTATION
25 mg / ml - 2 ml vial
ACTIONS
It inhibits the hydrogenetation of folic acid and prevents
its participation in the synthesis of purines and nucleic
acids. It also inhibits antibody synthesis.
INDICATIONS
Acute lymphoblastic leukemia, choriocarcinoma. It may
be used alone or in combination with other anticancer
agents in the management of breast cancer, particularly
squamous cell and small cell types, advanced stage non-hodgkin's
lymphoma, mycosis, fungoids, osterogenic sarcoma. It is
also useful in treatment of psoriasis.
CONTRAINDICATIONS
severe renal or hepatic disorders, pre-existing blood
dyscrasias, pregnancy, hypersensitivity to this drug.
WARNINGS
Methotrexate injection should not be administered intrathecally.
PREGNANCY
Methotrexate is contraindicated in pregnancy.
ADVERSE REACTIONS
Neurotoxicity, hepatotoxicity, hematological toxicity,
renal function impairement, gastrointestinal toxicity,
dermatological toxicity, allergic reactions, ocular toxicity,
cough, dyspnoea, malaise, osteoporosis, anaphylaxis, reversible
oligospermia, vasculitis have been observed.
DRUG INTERACTIONS
Folic acid and its derivatives may increase the effectiveness
of Methotrexate. The effects of Methotrexate may be enhanced
by concurrent administration of aminobenzoic acid, some
antibacterials, many anti-inflammatory agents, diuretics
and phenytoin. Fatal toxicity has occurred in patients
given NSAIDS, hepatotoxic or nephrotoxic agents concurrently
with Methotrexate.
OVERDOSAGE
leucovorin calcium (Folinic acid) should be administered
as soon as possible.
DOSAGE AND ADMINISTRATION
Acute lymphoblastic leukemia: Methotrexate IM in maintenance
dosage of 20-30 mg / m2 twice weekly is recommended.
Alternatively 2.5 mg / kg IV every 14 days.
Choricarcinoma: 15-30 mg daily for 5 days.
In palliation of inoperable solid tumors: 25-30 mg weekly
by IV injections.
